Heart transplantation provides long-term survival benefit in stable patients experiencing heart failure without reverse left ventricular remodeling

Transplantation

Volumn 82, Issue 11, 2006, Pages 1463-1471

  Meyer, Brigitte ^a   Moertl, Deddo ^a   Huelsmann, Martin ^a   Kulemann, Vanessa ^a   Zuckermann, Andreas ^a   Grimm, Michael ^a   Pacher, Richard ^a   Berger, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Heart failure; Prognosis; Remodeling; Transplantation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SPIRONOLACTONE;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEFIBRILLATOR; EVALUATION; FEMALE; HAZARD ASSESSMENT; HEART FAILURE; HEART GRAFT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATION; OUTPATIENT DEPARTMENT; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

FEMALE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 33845717970     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000246076.03174.21     Document Type: Article

References (39)

1. Hunt SA, Rider AK, Stinson EB, et al. Does cardiac transplantation prolong life and improve its quality? An updated report. Circulation 1976; 54(suppl): III56.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 2002; 21: 189.
3. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA Guidelines 2005 Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005; 112: e154.
4. Swedberg K, Cleland J, Dargie H, et al. ESC Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005; 26: 1115.
5. Stevenson LW, Rose EA. Left ventricular assist devices - bridges to transplantation, recovery, and destination for whom? Circulation 2003; 108: 3059.
6. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Report-2001. J Heart Lung Transplant 2001; 20: 805.
7. Marelli D, Laks H, Kobashigawa JA, et al. Seventeen-year experience with 1,083 heart transplants at a single institution. Ann Thorac Surg 2002; 74: 1558.
8. Hoercher K, McCarthy P, Young JB. Cardiac transplantation at the Cleveland Clinic Foundation. Clin Transpl 1999; 239.
9. Davies RA, Badovinac K, Haddad H, et al. Heart transplantation at the Ottawa Heart Institute: comparison with Canadian and international results. Artif Organs 2004; 28: 166.
10. Berger R, Strecker K, Hülsmann M, Frey B, Pacher R, Stanek B. Experience with β-blocker therapy in patients with advanced heart failure evaluated for HTx. J Heart Lung Transplant 2000; 19: 1081.
11. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the heart failure survival score for serial risk stratification in advanced heart failure. Am J Cardiol 2005; 95: 734.
12. Jimenez J, Bennett Edwards L, Higgins R, Bauerlein J, Pham S, Mallon S. Should stable UNOS 2 patients be transplanted? J Heart Lung Transplant 2005; 24: 178.
13. Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 2004; 43: 787.
14. Jong P, Yusuf S, Rousseau MF, Alm SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow up study. Lancet 2003; 361: 1843.
15. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society of for Heart Transplantation. J Heart Transplant 1990; 9: 587.
16. Zuckermann AO, Grimm M, Czerny M, et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000; 69: 1890.
17. Hülsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32: 1695.
18. Mentzer RM Jr, Jahania MS, Lasley RD, the US Multicenter FK506 Study Group. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation 1998; 65: 109.
19. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336.
20. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006; 6: 1387.
21. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507.
22. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 2006; 6: 993.
23. Van Gelder T, Shaw LM. The rational for and the limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80: S244.
24. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568.
25. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
26. Braunwald E. Expanding indications for beta-blockers in heart failure. N Engl J Med 2001; 344: 1711.
27. Berger R, Strecker K, Hülsmann M, et al. Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transplant 2003; 22: 1037.
28. Cicoira M, Davos CH, Francis DP, et al. Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. J Card Fail 2004; 10: 421.
29. Rostagno C, Olivo G, Comeglio M, et al. Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation. Eur J Heart Fail 2003; 5: 247.
30. Zugck C, Haunstetter A, Krüger C, et al. Impact of betablocker treatment on the prognostic value of currently risk predictors in congestive heart failure. J Am Coll Cardiol 2002; 39: 1615.
31. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Study Group. Circulation 1993; 87(suppl): VI5.
32. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998; 19: 696.
33. Berger R, Hülsmann M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392.
34. Ramahi TM, Longo MD, Cadariu AR, et al. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy. Eur Heart J 2001; 22: 849.
35. 99mTc-Tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy. J Nucl Med 2004; 45: 1878.
36. Packer M, Colucci WS, Cohn JN, et al., for the US Carvedilol Heart Failure Study Group. Relationship between long-term changes in left ventricular function and clinical outcome in patients with chronic heart failure treated with carvedilol. J Am Coll Cardiol 1997; 29: 64
37. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term β-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003; 145: 292.
38. Stevenson LW, Warner SL, Steimle AE, et al. The impending crisis awaiting cardiac transplantation: modeling a solution based on selection. Circulation 1994; 89: 450.
39. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539.